RPID reports 11% year-over-year revenue growth in Q2 2026, exceeding May guidance with $8.1 million in sales.
Rapid Micro Biosystems reported Q2 2026 revenue of $8.1 million, an 11% increase year-over-year and above the guidance issued in May. The company attributed the growth to stronger-than-expected validation activity in its core markets.
Management had previously guided for lower sequential growth but revised expectations upward following a surge in customer validations. The $8.1 million print compares with $7.3 million in Q2 2025 and $7.8 million in Q1 2026.
The company also outlined plans to achieve at least 27 validations by the end of 2026 and targets positive cash flow by the end of 2028.